Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.34
Q's Cash to Debt is ranked lower than
81% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.74 vs. Q: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
Q' s 10-Year Cash to Debt Range
Min: 0.19  Med: 0.36 Max: N/A
Current: 0.34
Equity to Asset -0.19
Q's Equity to Asset is ranked lower than
95% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. Q: -0.19 )
Ranked among companies with meaningful Equity to Asset only.
Q' s 10-Year Equity to Asset Range
Min: -0.55  Med: -0.22 Max: -0.17
Current: -0.19
-0.55
-0.17
Interest Coverage 5.87
Q's Interest Coverage is ranked lower than
84% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. Q: 5.87 )
Ranked among companies with meaningful Interest Coverage only.
Q' s 10-Year Interest Coverage Range
Min: 2.79  Med: 3.17 Max: 5.87
Current: 5.87
2.79
5.87
F-Score: 7
Z-Score: 3.71
M-Score: -1.43
WACC vs ROIC
6.04%
51.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.77
Q's Operating margin (%) is ranked higher than
75% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. Q: 10.77 )
Ranked among companies with meaningful Operating margin (%) only.
Q' s 10-Year Operating margin (%) Range
Min: 7.98  Med: 9.07 Max: 10.81
Current: 10.77
7.98
10.81
Net-margin (%) 6.41
Q's Net-margin (%) is ranked higher than
74% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.51 vs. Q: 6.41 )
Ranked among companies with meaningful Net-margin (%) only.
Q' s 10-Year Net-margin (%) Range
Min: 3.65  Med: 4.44 Max: 6.53
Current: 6.41
3.65
6.53
ROA (%) 11.24
Q's ROA (%) is ranked higher than
86% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. Q: 11.24 )
Ranked among companies with meaningful ROA (%) only.
Q' s 10-Year ROA (%) Range
Min: 7.36  Med: 9.66 Max: 20.82
Current: 11.24
7.36
20.82
ROC (Joel Greenblatt) (%) 314.40
Q's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. Q: 314.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
Q' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 211.6  Med: 268.09 Max: 316.24
Current: 314.4
211.6
316.24
» Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

Q Guru Trades in Q2 2014

Ron Baron 402,309 sh (+22.91%)
Vanguard Health Care Fund 5,636,278 sh (+20.27%)
Steven Cohen 11,300 sh (unchged)
Caxton Associates Sold Out
Jim Simons 433,100 sh (-4.03%)
Paul Tudor Jones 12,942 sh (-27.76%)
Joel Greenblatt 7,008 sh (-60.33%)
» More
Q3 2014

Q Guru Trades in Q3 2014

Joel Greenblatt 477,607 sh (+6715.17%)
Paul Tudor Jones 24,488 sh (+89.21%)
Ron Baron 402,749 sh (+0.11%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Steven Cohen Sold Out
Jim Simons 237,400 sh (-45.19%)
» More
Q4 2014

Q Guru Trades in Q4 2014

Steven Cohen 99,500 sh (New)
Ken Fisher 7,700 sh (New)
Jim Simons 574,300 sh (+141.91%)
Joel Greenblatt 747,251 sh (+56.46%)
Ron Baron 427,749 sh (+6.21%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Paul Tudor Jones 22,811 sh (-6.85%)
» More
Q1 2015

Q Guru Trades in Q1 2015

Ron Baron 465,743 sh (+8.88%)
Jim Simons 576,700 sh (+0.42%)
Ken Fisher 7,717 sh (+0.22%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 15,292 sh (-32.96%)
Joel Greenblatt 402,994 sh (-46.07%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.75
Q's P/E(ttm) is ranked higher than
60% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.30 vs. Q: 26.75 )
Ranked among companies with meaningful P/E(ttm) only.
Q' s 10-Year P/E(ttm) Range
Min: 20.63  Med: 24.76 Max: 31.56
Current: 26.75
20.63
31.56
Forward P/E 20.58
Q's Forward P/E is ranked lower than
58% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.69 vs. Q: 20.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.80
Q's PE(NRI) is ranked higher than
61% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.40 vs. Q: 26.80 )
Ranked among companies with meaningful PE(NRI) only.
Q' s 10-Year PE(NRI) Range
Min: 20.62  Med: 24.74 Max: 31.48
Current: 26.8
20.62
31.48
P/S 1.71
Q's P/S is ranked higher than
71% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. Q: 1.71 )
Ranked among companies with meaningful P/S only.
Q' s 10-Year P/S Range
Min: 1.02  Med: 1.35 Max: 1.73
Current: 1.71
1.02
1.73
PFCF 30.01
Q's PFCF is ranked lower than
53% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.29 vs. Q: 30.01 )
Ranked among companies with meaningful PFCF only.
Q' s 10-Year PFCF Range
Min: 18.77  Med: 23.22 Max: 35.38
Current: 30.01
18.77
35.38
POCF 23.80
Q's POCF is ranked lower than
55% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.37 vs. Q: 23.80 )
Ranked among companies with meaningful POCF only.
Q' s 10-Year POCF Range
Min: 14.3  Med: 18.08 Max: 24.02
Current: 23.8
14.3
24.02
EV-to-EBIT 17.62
Q's EV-to-EBIT is ranked higher than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. Q: 17.62 )
Ranked among companies with meaningful EV-to-EBIT only.
Q' s 10-Year EV-to-EBIT Range
Min: 14.8  Med: 16.50 Max: 18.3
Current: 17.62
14.8
18.3
Current Ratio 1.59
Q's Current Ratio is ranked lower than
78% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. Q: 1.59 )
Ranked among companies with meaningful Current Ratio only.
Q' s 10-Year Current Ratio Range
Min: 1.15  Med: 1.36 Max: 1.59
Current: 1.59
1.15
1.59
Quick Ratio 1.59
Q's Quick Ratio is ranked lower than
67% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. Q: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
Q' s 10-Year Quick Ratio Range
Min: 1.15  Med: 1.36 Max: 1.59
Current: 1.59
1.15
1.59
Days Sales Outstanding 66.90
Q's Days Sales Outstanding is ranked lower than
51% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. Q: 66.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
Q' s 10-Year Days Sales Outstanding Range
Min: 25.13  Med: 27.57 Max: 29.74
Current: 66.9
25.13
29.74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.27
Q's Price/Median PS Value is ranked lower than
67% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. Q: 1.27 )
Ranked among companies with meaningful Price/Median PS Value only.
Q' s 10-Year Price/Median PS Value Range
Min: 0.76  Med: 0.98 Max: 1.17
Current: 1.27
0.76
1.17
Earnings Yield (Greenblatt) (%) 5.71
Q's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. Q: 5.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
Q' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 5.5  Med: 6.00 Max: 6.8
Current: 5.71
5.5
6.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:QTS.Germany,
Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcing services. The Company's services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and functional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides management consulting services based on life science expertise and analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical devices, such as the FDA's regulati
» More Articles for Q

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 
Qwest to Webcast Third Quarter 2009 Earnings Conference Call Sep 03 2009 
Qwest Reports Second Quarter 2009 Results Jul 29 2009 
Qwest Reports Fourth Quarter and Full Year 2008 Results Feb 10 2009 
Qwest Communications Announces Tax Treatment for 2008 Dividends Jan 19 2009 

More From Other Websites
Quintiles, Quest officially launch Q2 Solutions with focus on personalized medicine Jul 06 2015
Quintiles and Quest Diagnostics Launch Q2 Solutions Jul 02 2015
Quintiles and Quest Diagnostics Launch Q2 Solutions Jul 02 2015
Quintiles’ Second Quarter 2015 Earnings Call Scheduled for Wednesday, July 29th Jul 01 2015
Quintiles’ Second Quarter 2015 Earnings Call Scheduled for Wednesday, July 29th Jul 01 2015
Quintiles Doc Rescues Unconscious Woman On Long-Haul Airline Flight Jun 29 2015
Quintiles Introduces Infosario One Mobile App Jun 16 2015
Quintiles Introduces Infosario One Mobile App Jun 16 2015
Edited Transcript of Q presentation 12-May-15 7:00pm GMT Jun 16 2015
Quintiles Unveils New Predictive and Advanced Analytics Capabilities to Enhance its Risk-Based... Jun 15 2015
Quintiles Presentation at Jefferies Global Healthcare Conference Rescheduled for Wednesday, June 3rd Jun 02 2015
Analyst Offers Top US Growth Stock Calls for This Week Jun 02 2015
CORRECTING and REPLACING Quintiles Officially Opens Greater China Regional Headquarters in Shanghai May 31 2015
CORRECTING and REPLACING Quintiles Officially Opens Greater China Regional Headquarters in Shanghai May 31 2015
Quintiles Officially Opens Greater China Regional Headquarters in Shanghai May 29 2015
Quintiles Officially Opens Greater China Regional Headquarters in Shanghai May 29 2015
Quintiles CEO to Present at William Blair 35th Annual Growth Stock Conference May 26 2015
Quintiles CEO to Present at William Blair 35th Annual Growth Stock Conference May 26 2015
Quintiles Transnational upgraded by Sun Trust Rbsn Humphrey May 26 2015
Quintiles Launches New Solution to Meet Needs of Asia-Pacific Emerging Biopharmaceutical Companies May 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK